[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE453653T1 - Platinkomplexe zur behandlung von tumoren - Google Patents

Platinkomplexe zur behandlung von tumoren

Info

Publication number
ATE453653T1
ATE453653T1 AT04781131T AT04781131T ATE453653T1 AT E453653 T1 ATE453653 T1 AT E453653T1 AT 04781131 T AT04781131 T AT 04781131T AT 04781131 T AT04781131 T AT 04781131T AT E453653 T1 ATE453653 T1 AT E453653T1
Authority
AT
Austria
Prior art keywords
tumors
platinum complexes
treatment
stat
inhibition
Prior art date
Application number
AT04781131T
Other languages
English (en)
Inventor
Heidi Kay
Jay Palmer
Joseph Stanko
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of ATE453653T1 publication Critical patent/ATE453653T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04781131T 2003-08-13 2004-08-13 Platinkomplexe zur behandlung von tumoren ATE453653T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48122603P 2003-08-13 2003-08-13
US51558003P 2003-10-30 2003-10-30
US51994303P 2003-11-14 2003-11-14
US52529503P 2003-11-25 2003-11-25
PCT/US2004/026393 WO2005016946A2 (en) 2003-08-13 2004-08-13 Platinum complexes for the treatment of tumors

Publications (1)

Publication Number Publication Date
ATE453653T1 true ATE453653T1 (de) 2010-01-15

Family

ID=34199238

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04809566T ATE404574T1 (de) 2003-08-13 2004-08-13 Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
AT04781131T ATE453653T1 (de) 2003-08-13 2004-08-13 Platinkomplexe zur behandlung von tumoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04809566T ATE404574T1 (de) 2003-08-13 2004-08-13 Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden

Country Status (8)

Country Link
US (6) US7238372B2 (de)
EP (2) EP1664070B1 (de)
JP (2) JP2007502777A (de)
AT (2) ATE404574T1 (de)
AU (3) AU2004270655B2 (de)
CA (2) CA2535762A1 (de)
DE (2) DE602004015811D1 (de)
WO (2) WO2005016946A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016946A2 (en) * 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20050288365A1 (en) * 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
EP1748772A2 (de) * 2004-04-09 2007-02-07 University Of South Florida Kombinationstherapien für krebs und proliferative gefässerkrankungen
WO2007008247A2 (en) 2004-11-10 2007-01-18 University Of South Florida Platinum complexes for targeted drug delivery
WO2006065894A2 (en) 2004-12-14 2006-06-22 University Of South Florida Methods for inhibiting stat3 signaling in immune cells
DE102004060934A1 (de) * 2004-12-17 2006-06-29 Wacker Chemie Ag Vernetzbare Polyorganosiloxanmassen
JP5193032B2 (ja) * 2005-06-30 2013-05-08 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド モノアゾールリガンド白金類似体
US20100190180A1 (en) * 2005-07-06 2010-07-29 Heidi Kay Materials and Methods for Screening, Diagnosis and Prognosis of Conditions Associated With Stat Protein Expression
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
WO2007047623A2 (en) * 2005-10-14 2007-04-26 University Of South Florida Methods of inhibiting cell growth and methods of enhancing radiation responses
DE102006040647A1 (de) * 2006-08-30 2008-03-13 Robert Bosch Gmbh Handwerkzeugmaschine
US8895610B1 (en) 2007-05-18 2014-11-25 Heldi Kay Platinum (IV) compounds targeting zinc finger domains
US8026382B2 (en) 2007-05-18 2011-09-27 Heidi Kay Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
CA2691047A1 (en) * 2007-06-18 2008-12-24 Platco Technologies (Proprietary) Limited Platinum (iv) complexes
ES2584904T3 (es) 2007-09-10 2016-09-30 Boston Biomedical, Inc. Nuevas composiciones y métodos para el tratamiento del cáncer
US20100184854A1 (en) * 2008-12-12 2010-07-22 Platco Technologies (Proprietary) Limited Platinum (iv) complexes and methods of use thereof
DK3012329T3 (da) 2010-06-18 2017-11-20 Myriad Genetics Inc Fremgangsmåder og materialer til at vurdere tab af heterozygositet
AU2011293635B2 (en) 2010-08-24 2015-11-26 Children's Medical Center Corporation Methods for predicting anti-cancer response
EP3693473A1 (de) 2011-06-17 2020-08-12 Myriad Genetics, Inc. Methoden und materialien zur beurteilung des allelischen ungleichgewichts
RU2491936C2 (ru) * 2011-07-11 2013-09-10 Борис Николаевич Анисимов Способ комплексного лечения больных паразитарными заболеваниями
ES2759533T5 (es) 2011-12-21 2023-06-22 Myriad Genetics Inc Métodos y materiales para evaluar la pérdida de heterocigosidad
CA3080441A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
RU2682674C2 (ru) 2013-03-15 2019-03-20 Шерри Энн МАКФАРЛЭНД Координационные комплексы на основе металлов в качестве фотодинамических соединений и их применение
US20140363521A1 (en) 2013-04-05 2014-12-11 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
CN104230997B (zh) * 2013-06-13 2017-01-04 上海医药工业研究院 一种铂（ⅱ）配合物、其制备方法、药物组合物及应用
WO2015013565A1 (en) * 2013-07-25 2015-01-29 Nemucore Medical Innovations, Inc. Platinum derivatives for hydrophobic formulations
EP3080292B1 (de) 2013-12-09 2022-02-02 Institut Curie Verfahren zum nachweis der inaktivierung des homologen rekombinationssignalwegs (brca1/2) bei menschlichen tumoren
ES2800673T3 (es) 2014-08-15 2021-01-04 Myriad Genetics Inc Métodos y materiales para evaluar una deficiencia de recombinación homóloga
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
KR20180014834A (ko) 2015-06-19 2018-02-09 신-낫 프로덕츠 엔터프라이즈 엘엘씨 카보플라틴을 함유하는 조성물 및 용도
CN116854745A (zh) 2015-06-25 2023-10-10 新纳特产品公司 药物共晶组合物及其用途
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
MX2020005310A (es) 2017-11-21 2020-10-08 Medoncare Pharmaceutical Co Ltd Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.
CN112175014B (zh) * 2020-10-10 2021-08-20 中国药科大学 一种一氧化氮供体型四价铂衍生物、制备方法及其医药用途
EP4141127B1 (de) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Verfahren zur bewertung des mangels an homologer rekombination in eierstockkrebszellen
WO2024063828A1 (en) 2022-09-21 2024-03-28 Oracle International Corporation Expert-optimal correlation: contamination factor identification for unsupervised anomaly detection

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
GB1432563A (en) * 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GR851932B (de) * 1984-08-14 1985-12-13 Engelhard Corp
JPS6296A (ja) * 1985-03-06 1987-01-06 Sumitomo Pharmaceut Co Ltd 脂溶性白金（２）錯体
JPH01156989A (ja) * 1987-09-25 1989-06-20 Ss Pharmaceut Co Ltd 新規白金錯体
ATE113054T1 (de) * 1988-02-02 1994-11-15 Johnson Matthey Inc Pt(iv) komplexe.
JP3520367B2 (ja) * 1994-12-22 2004-04-19 独立行政法人産業技術総合研究所 白金ニトロアンミン系錯体の製造方法
US6008395A (en) * 1995-02-28 1999-12-28 Kidani; Yoshinori Platinum (IV) complex, production process thereof and carcinostatic agent containing the same
US5922689A (en) * 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US5849790A (en) * 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
US6145688A (en) * 1996-07-17 2000-11-14 Smith; James C. Closure device for containers
US5977393A (en) 1997-11-21 1999-11-02 California Institute Of Technology Schiff base derivatives of ruthenium and osmium olefin metathesis catalysts
KR100246722B1 (ko) * 1997-12-30 2000-04-01 박호군 경구용 백금 착화합물 항암제 및 그 제조방법
JP2002535247A (ja) * 1998-11-26 2002-10-22 ペンタファルム アクチェンゲゼルシャフト 輸送系複合体
AU2736400A (en) * 1999-01-27 2000-08-18 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
JP4387669B2 (ja) * 2000-10-13 2009-12-16 ザイジェン エス．アー． 新規なトランスポーターペプチド配列による生物学的エフェクターの細胞内送達
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US7754684B2 (en) 2003-06-11 2010-07-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
WO2005016946A2 (en) * 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20050288365A1 (en) 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
WO2007008247A2 (en) 2004-11-10 2007-01-18 University Of South Florida Platinum complexes for targeted drug delivery
US20100190180A1 (en) 2005-07-06 2010-07-29 Heidi Kay Materials and Methods for Screening, Diagnosis and Prognosis of Conditions Associated With Stat Protein Expression

Also Published As

Publication number Publication date
WO2005016946A2 (en) 2005-02-24
WO2005023824A2 (en) 2005-03-17
US7763585B2 (en) 2010-07-27
US20090285884A1 (en) 2009-11-19
AU2004264421B2 (en) 2011-02-24
WO2005016946A3 (en) 2005-09-29
US8247445B2 (en) 2012-08-21
AU2004270655B2 (en) 2011-03-24
EP1664070A2 (de) 2006-06-07
DE602004024909D1 (de) 2010-02-11
WO2005023824A3 (en) 2005-06-09
AU2004264421A1 (en) 2005-02-24
US7566798B2 (en) 2009-07-28
US20050080131A1 (en) 2005-04-14
US20100310645A1 (en) 2010-12-09
AU2004270655A1 (en) 2005-03-17
ATE404574T1 (de) 2008-08-15
US7238372B2 (en) 2007-07-03
EP1675864A2 (de) 2006-07-05
US20050074502A1 (en) 2005-04-07
AU2011202386A1 (en) 2011-06-09
US7759510B2 (en) 2010-07-20
EP1675864B1 (de) 2009-12-30
EP1664070B1 (de) 2008-08-13
US20080187992A1 (en) 2008-08-07
US8598230B2 (en) 2013-12-03
US20100316704A1 (en) 2010-12-16
JP2007502777A (ja) 2007-02-15
JP2007502301A (ja) 2007-02-08
DE602004015811D1 (de) 2008-09-25
CA2535584A1 (en) 2005-02-24
CA2535762A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
NO20055741D0 (no) Nye kjemiske forbindelser
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties